ProfileGDS5678 / 1423358_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 76% 72% 76% 73% 71% 58% 65% 73% 74% 78% 76% 71% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9949666
GSM967853U87-EV human glioblastoma xenograft - Control 25.0912476
GSM967854U87-EV human glioblastoma xenograft - Control 34.64272
GSM967855U87-EV human glioblastoma xenograft - Control 45.1827876
GSM967856U87-EV human glioblastoma xenograft - Control 54.6494673
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3945571
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.599558
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9486765
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7208973
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8365374
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4280978
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2009276
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5009871
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1386376